Abstract 1573: Combinatorial antitumor effects of CD3-based trispecific T cell activating constructs (TriTACs) and checkpoint inhibitors in preclinical models

Authors: Mary Ellen Molloy, Laura B. Valenzuela, Priyanka E. Basak, Che-Leung Law

Published: 2021-07-01

DOI: 10.1158/1538-7445.am2021-1573

Source: Full article